Antithrombotic effects of low-molecular-weight heparin calcium (LMWH-Ca) in experimental models

General Pharmacology

Volumn 33, Issue 2, 1999, Pages 207-211

  Ji, H ^a   Li, S P ^a,b   Cheng, X ^c   Cheng, H R ^c   Ng, T B ^b   Li, P ^a   Li, N S ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

Antithrombotic agent; Heparin; Low molecular weight heparin

Indexed keywords

HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; LOW MOLECULAR WEIGHT HEPARIN CALCIUM; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTERY THROMBOSIS; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DOSE RESPONSE; IN VITRO STUDY; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT; VEIN THROMBOSIS;

ANIMALS; ANTICOAGULANTS; ARTERIOVENOUS SHUNT, SURGICAL; CORONARY THROMBOSIS; FIBRINOLYTIC AGENTS; HEPARIN; MALE; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; VENOUS THROMBOSIS;

EID: 0032790574     PISSN: 03063623     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-3623(98)00276-6     Document Type: Article

References (19)

1. Amar J., Caranobe C., Sie P., Boneu B. Antithrombotic potencies of heparins in relation to their antifactor Xa and antithrombin activities. an experimental study in two models of thrombosis in the rabbit Brit J Haematol. 76:1990;94-100.
2. Andersson L.O., Barrowcliffe T.W., Holme E., Johnson E.A., Sonderstrom G. Anticoagulant properties of heparin fractionated by affinity chromatography on matrixbound Antithrombin III and by gel filtration. Thromb Res. 9:1976;575-583.
3. Andersson L.O., Barrowcliffe T.W., Holme E., Jonhson E.A., Sonderstrom G. Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of the heparin neutralization in plasma. Thromb Res. 15:1979;531-541.
4. Cadroy Y., Harker L.A., Hanson S.R. Inhibition of platelet-dependent thrombosis by low molecular weight heparin (CY 222). comparison with standard heparin J Lab Clin Med. 114:1989;349-357.
5. Carter C.J., Kelton J.G., Cerskus A., Santos A.V., Gent M. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood. 59:1982;1239-1245.
6. Green D., Hirsh J., Heit J., Prins M., Davidson B., Lensing A.W.A. Low molecular weight heparin. a critical analysis of clinical trials Pharmcol Rev. 46:1994;89-109.
7. Hladovec J. Experimental arterial thrombosis in rats with continuous registration. Thromb Diath Haemorrh. 26:1974;407-410.
8. Holmer E., Lindahl U., Bäckström G., Thunberg L., Sandberg H., Söderstrom G., Andersson L.O. Anticoagulant activities and effects on platelets of a heparin fragment with high affinity for antithrombin. Thromb Res. 18:1980;861-869.
9. Jordan R.E., Oosta G.M., Garder W.T., Rosenberg R.D. The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin. J Biol Chem. 255:1980;10081-10090.
10. Lane D.A., MacGregor I.R., Michalski R., Kakkar V.V. Anticoagulant activities of four unfractionated and fractionated heparins. Thromb Res. 12:1978;257-271.
11. Lane D.A., Denton J., Flynn A.M., Thunberg L., Lindahl U. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem J. 218:1984;725-732.
12. Levine M.N., Hirsh J., Kelton J.G. Heparin-induced bleeding. Lane D.A., Lindahl U. Heparin. 1989;517-531 Chemical and biological properties, clinical applications, Amold E, London-Melbourne-Auckland.
13. Ockelford P.A., Carter C.J., Mitchell L., Hirsh J. Discordance between the anti-Xa activity and the antithrombotic activity of an ultra-low molecular weight heparin fraction. Thromb Res. 28:1982;401-409.
14. Proctor P.A., Rapport S.I. The partial thromboplastin time with kaolin. Am J Clin Pathol. 3:1961;212-219.
15. Tew C.J., Lane D.A., Thompson E., Ireland H., Curtis J.R. Relationship between ex vivo anti-proteinase (factor Xa and thrombin) assays and in vivo anticoagulant effect of very low molecular weight heparin, CY 222. Brit J Haematol. 70:1988;335-340.
16. Umetsu T., Sanai K. Effect of 1-methyl-2-mercapto-5(3-pyridyl)-imidazole(KC-6141), an anti-aggregating compound, on experimental thrombosis in rats. Thromb Haemostas. 39:1978;74-83.
17. Van Ryn-McKenna J., Gray E., Weber E., Ofosu F., Buchanan M.R. Effect of sulfated polysaccharides on inhibition of thrombus formation initiated by different stimuli. Thromb Haemostas. 61:1989;7-9.
18. Weitz J. New anticoagulant strategies. Current status and future potential. Drugs. 48:1994;485-497.
19. Wessler S., Reimer S.M., Sheps M.C. Biological assay of a thrombosis inducing activity in human serum. J Appl Physiol. 14:1959;943-946.